Targeting the Receptor of Glial Cell Line-Derived Neurotrophic factor to treat Parkinson’s Disease
Objective: Our goal is to develop small molecules which support and restore nigrostriatal dopamine neurons by activation of glial cell line-derived-neurotrophic factor (GDNF) receptors. Background:…Association between prediagnostic symptoms and patterns of treatment initiation in people with Parkinson´s disease in the United Kingdom
Objective: To explore the association between prediagnostic symptoms and treatment initiation in people with Parkinson´s disease (PD) Background: Prediagnostic symptoms in people with PD may…Dose Optimization of Apomorphine Sublingual Film for On-Demand Treatment of “OFF” Episodes in Patients with Parkinson’s Disease: Clinical and Exposure Response Findings
Objective: Evaluate if dose optimization (DO) of apomorphine sublingual film (APL-130277; APL) can achieve improved FULL “ON” response in patients with Parkinson’s disease (PD) and…An Analysis of Parkinson’s Disease Medication Treatment Patterns among Medicaid Patients
Objective: To describe patient demographic and medication utilization patterns within a state Medicaid program for patients diagnosed with Parkinson’s disease (PD). Background: Little is known…Efficacy and safety of istradefylline in Parkinson’s disease patients with postural abnormality: Results from a multicenter, open-label study in Japan
Objective: To investigate the efficacy and safety of istradefylline for the treatment of postural abnormality in patients with Parkinson’s disease (PD). Background: Postural abnormality in…Preclinical pharmacology and early clinical development of dopamine D1 positive allosteric modulators (D1PAMs) with therapeutic potential for neuropsychiatric disorders
Objective: The objective was to characterize novel dopamine D1PAMs pre-clinically in behavioral and neurochemical models and in phase 1 human studies in healthy volunteers and…Long-term effects of ADS-5102 (amantadine) extended release capsules on OFF symptoms in Parkinson’s disease patients with levodopa-induced dyskinesia: Analysis of EASE LID 2 trial
Objective: Evaluate the long-term effect of ADS-5102 on OFF time among Parkinson’s disease (PD) patients with levodopa-induced dyskinesia (LID). Background: ADS-5102, the only drug FDA-approved…Effect of opicapone and entacapone on daily pattern of motor fluctuations in Parkinson’s disease patients
Objective: To evaluate the effect of opicapone (OPC) 50 mg versus entacapone (ENT) on daily pattern of motor fluctuations. Background: OPC, a once-daily catechol-O-methyltransferase inhibitor,…Effect of opicapone and entacapone on early morning-OFF pattern in Parkinson’s disease patients with motor fluctuations
Objective: To evaluate the effect of opicapone (OPC) 50 mg versus entacapone (ENT) on early morning-OFF (EMO) pattern. Background: OPC, a once-daily catechol-O-methyltransferase inhibitor, was…Oral treatment of the SOD1G93A transgenic mouse model of amyotrophic lateral sclerosis (ALS) with the neuro-inflammation inhibiting compound PRI-003
Objective: Demonstration of beneficial effects of neuro-inflammation inhibition for the treatment of amyotrophic lateral sclerosis (ALS). Background: Neuro-inflammation and immune-inflammatory processes are characteristics of the…
- « Previous Page
- 1
- …
- 17
- 18
- 19
- 20
- 21
- …
- 34
- Next Page »